Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 2
1956 8
1957 1
1958 3
1959 1
1962 1
1963 1
1964 3
1965 8
1966 2
1967 2
1968 3
1969 4
1970 2
1974 1
1980 2
1981 3
1982 3
1983 4
1984 6
1985 12
1986 2
1987 8
1988 11
1989 11
1990 8
1991 6
1992 2
1993 5
1994 10
1995 7
1996 6
1997 5
1998 5
1999 3
2000 11
2001 11
2002 11
2003 12
2004 11
2005 5
2006 16
2007 22
2008 18
2009 22
2010 17
2011 21
2012 19
2013 18
2014 14
2015 26
2016 23
2017 21
2018 24
2019 34
2020 38
2021 8
Text availability
Article attribute
Article type
Publication date

Search Results

515 results
Results by year
Filters applied: . Clear all
Page 1
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Sanz RG, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous JV, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Trotman J, Chan WY, Schneider J, Ro S, Cohen A, Huang J, Dimopoulos M. Tam CS, et al. Among authors: tedeschi a. Blood. 2020 Oct 29;136(18):2038-2050. doi: 10.1182/blood.2020006844. Blood. 2020. PMID: 32731259 Free PMC article. Clinical Trial.
Adaptable haemodynamic endothelial cells for organogenesis and tumorigenesis.
Palikuqi B, Nguyen DT, Li G, Schreiner R, Pellegata AF, Liu Y, Redmond D, Geng F, Lin Y, Gómez-Salinero JM, Yokoyama M, Zumbo P, Zhang T, Kunar B, Witherspoon M, Han T, Tedeschi AM, Scottoni F, Lipkin SM, Dow L, Elemento O, Xiang JZ, Shido K, Spence JR, Zhou QJ, Schwartz RE, De Coppi P, Rabbany SY, Rafii S. Palikuqi B, et al. Among authors: tedeschi am. Nature. 2020 Sep;585(7825):426-432. doi: 10.1038/s41586-020-2712-z. Epub 2020 Sep 9. Nature. 2020. PMID: 32908310 Free PMC article.
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators. Burger JA, et al. Among authors: tedeschi a. N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6. N Engl J Med. 2015. PMID: 26639149 Free PMC article. Clinical Trial.
Transduction of DNA information through water and electromagnetic waves.
Montagnier L, Del Giudice E, Aïssa J, Lavallee C, Motschwiller S, Capolupo A, Polcari A, Romano P, Tedeschi A, Vitiello G. Montagnier L, et al. Among authors: tedeschi a. Electromagn Biol Med. 2015;34(2):106-12. doi: 10.3109/15368378.2015.1036072. Electromagn Biol Med. 2015. PMID: 26098521 Review.
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ. Burger JA, et al. Among authors: tedeschi a. Leukemia. 2020 Mar;34(3):787-798. doi: 10.1038/s41375-019-0602-x. Epub 2019 Oct 18. Leukemia. 2020. PMID: 31628428 Free PMC article. Clinical Trial.
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V, Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF, Styles L, Flinn IW. Moreno C, et al. Among authors: tedeschi a. Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3. Lancet Oncol. 2019. PMID: 30522969 Clinical Trial.
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Dimopoulos MA, et al. Among authors: tedeschi a. N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1. N Engl J Med. 2018. PMID: 29856685 Free article. Clinical Trial.
Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia.
Castillo JJ, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, Kersten MJ, Leblond V, Minnema MC, Owen RG, Palomba ML, Talaulikar D, Tedeschi A, Trotman J, Varettoni M, Vos JM, Treon SP, Kastritis E. Castillo JJ, et al. Among authors: tedeschi a. Lancet Haematol. 2020 Nov;7(11):e827-e837. doi: 10.1016/S2352-3026(20)30224-6. Lancet Haematol. 2020. PMID: 33091356 Review.
Waldenstrom's Macroglobulinemia: An Update.
Mazzucchelli M, Frustaci AM, Deodato M, Cairoli R, Tedeschi A. Mazzucchelli M, et al. Among authors: tedeschi a. Mediterr J Hematol Infect Dis. 2018 Jan 1;10(1):e2018004. doi: 10.4084/MJHID.2018.004. eCollection 2018. Mediterr J Hematol Infect Dis. 2018. PMID: 29326801 Free PMC article. Review.
515 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page